HUTCHMED (CHINA) LIMITED - AMERICAN DEPOSITARY SHA

HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer

29 يناير 2024 23:53:49 بحسب Nasdaq GlobeNewswire

HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

10 يناير 2024 19:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms

12 ديسمبر 2023 23:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China

12 ديسمبر 2023 19:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses

30 نوفمبر 2023 19:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

08 نوفمبر 2023 19:11:18 بحسب Nasdaq GlobeNewswire

HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023

16 أكتوبر 2023 04:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

29 سبتمبر 2023 04:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer

12 سبتمبر 2023 04:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China

11 سبتمبر 2023 20:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer

28 أغسطس 2023 20:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China

20 أغسطس 2023 20:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Reports 2023 Interim Results and Provides Business Updates

31 يوليو 2023 07:41:53 بحسب Nasdaq GlobeNewswire

HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study

19 يوليو 2023 20:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Announces Changes to Board of Directors and Technical Committee 

13 يوليو 2023 04:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Initiates Phase I Study of its novel SHP2 inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China

09 يوليو 2023 20:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED to Announce 2023 Half-Year Financial Results

26 يونيو 2023 04:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet

15 يونيو 2023 20:30:00 بحسب Nasdaq GlobeNewswire

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

15 يونيو 2023 10:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Highlights Presentations for Hematological Malignancy Programs at the 2023 EHA and ICML Meetings

09 يونيو 2023 05:30:00 بحسب Nasdaq GlobeNewswire